Skip to main content
Top
Published in: BMC Hematology 1/2004

Open Access 01-12-2004 | Case report

Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)

Authors: Fotios P Panitsas, Athanasia Mouzaki

Published in: BMC Hematology | Issue 1/2004

Login to get access

Abstract

Background

In view of clinical observations and laboratory results that support a central role of the spleen in idiopathic thrombocytopenic purpura (ITP) pathophysiology, we studied the effect of splenectomy on type-1 and type-2 cytokine gene expression in an adult ITP case, refractory to conservative treatment.

Case presentation

The patient was subjected to splenectomy 9 months after the diagnosis with complete response, attaining platelet counts over 150 × 106/L within 10 days after the operation. Two consecutive blood samples were obtained from the patient, 3 and 7 months after the splenectomy for the purposes of this study. A control group consisted of 11 healthy adults. Peripheral blood mononuclear cells were prepared from each blood sample and cultured in vitro for 8 h with the addition of the mitogens phorbol myristate acetate and ionomycin. Total cellular RNA extracted from 106 cells was submitted to semiquantitave reverse transcriptase-polymerase chain reaction (RT-PCR) for the amplification of IL-2, IFN-γ, IL-4, IL-5, and IL-10 metagraphs. The PCR products were run on ethidium-stained agarose gels, photographed and quantified by densitometry.
A steep decrease of type-1 cytokine expression (IL-2, IFN-γ) and their calculated sum expressing Th1 activity was observed at 7 months post-splenectomy compared to 3 months post-splenectomy, in parallel with a rise of platelet count from 190 × 106/L to 265 × 106/L. The change of type-2 cytokine expression (IL-4, IL-5, IL-10) was slight and the Th2 activity (IL-4+IL-5) remained largely unchanged. The Th1/Th2 ratio, that reflects the pathogenic disease-specific T-cell immune deviation, was accordingly reduced 7 months post-splenectomy (Th1/Th2 = 1.3) compared to 3 months (Th1/Th2 = 3.5).

Conclusions

The reduction of the Th1/Th2 cytokine ratio that was observed over time after splenectomy was accompanied by full clinical remission. Nevertheless, the persistence of a type-1 polarization, even after several months following spleen removal, is suggestive of a more basic abnormality of the immune function in these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med. 2002, 346: 995-1008. 10.1056/NEJMra010501.CrossRefPubMed Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med. 2002, 346: 995-1008. 10.1056/NEJMra010501.CrossRefPubMed
2.
go back to reference McMillan R: The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000, 37: 5-9.CrossRefPubMed McMillan R: The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000, 37: 5-9.CrossRefPubMed
3.
go back to reference Hed J: Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl. 1998, 424: 37-40. 10.1080/080352598750030726.CrossRefPubMed Hed J: Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl. 1998, 424: 37-40. 10.1080/080352598750030726.CrossRefPubMed
4.
go back to reference Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H: T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003, 9: 1123-1124. 10.1038/nm921.CrossRefPubMed Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H: T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003, 9: 1123-1124. 10.1038/nm921.CrossRefPubMed
5.
go back to reference Kuwana M, Kaburaki J, Ikeda Y: Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998, 102: 1393-1402.CrossRefPubMedPubMedCentral Kuwana M, Kaburaki J, Ikeda Y: Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998, 102: 1393-1402.CrossRefPubMedPubMedCentral
6.
go back to reference Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J: Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996, 87: 4245-4254.PubMed Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J: Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996, 87: 4245-4254.PubMed
7.
go back to reference Coopamah MD, Garvey MB, Freedman J, Semple JW: Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev. 2003, 17: 69-80. 10.1053/tmrv.2003.50004.CrossRefPubMed Coopamah MD, Garvey MB, Freedman J, Semple JW: Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev. 2003, 17: 69-80. 10.1053/tmrv.2003.50004.CrossRefPubMed
8.
go back to reference Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A: Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004, 103: 2645-2647. 10.1182/blood-2003-07-2268.CrossRefPubMed Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A: Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004, 103: 2645-2647. 10.1182/blood-2003-07-2268.CrossRefPubMed
9.
go back to reference Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y: Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002, 168: 3675-3682.CrossRefPubMed Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y: Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002, 168: 3675-3682.CrossRefPubMed
10.
go back to reference Sandler SG: The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000, 37: 10-12.CrossRefPubMed Sandler SG: The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000, 37: 10-12.CrossRefPubMed
11.
go back to reference Najean Y, Rain JD, Billotey C: The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol. 1997, 97: 547-550. 10.1046/j.1365-2141.1997.832723.x.CrossRefPubMed Najean Y, Rain JD, Billotey C: The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol. 1997, 97: 547-550. 10.1046/j.1365-2141.1997.832723.x.CrossRefPubMed
12.
go back to reference McMillan R: Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000, 37: 239-248.CrossRefPubMed McMillan R: Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000, 37: 239-248.CrossRefPubMed
13.
go back to reference Mazzucconi MG, Arista MC, Peraino M, Chistolini A, Felici C, Francavilla V, Macale E, Conti L, Gandolfo GM: Long-term follow-up of autoimmune thrombocytopenic purpura (ATP) patients submitted to splenectomy. Eur J Haematol. 1999, 62: 219-222.CrossRefPubMed Mazzucconi MG, Arista MC, Peraino M, Chistolini A, Felici C, Francavilla V, Macale E, Conti L, Gandolfo GM: Long-term follow-up of autoimmune thrombocytopenic purpura (ATP) patients submitted to splenectomy. Eur J Haematol. 1999, 62: 219-222.CrossRefPubMed
14.
go back to reference Aster RH, George JN, McMillan R, Ganguly P: Workshop on autoimmune (idiopathic) thrombocytopenic purpura: pathogenesis and new approaches to therapy. Am J Hematol. 1998, 58: 231-234. 10.1002/(SICI)1096-8652(199807)58:3<231::AID-AJH12>3.0.CO;2-C.CrossRefPubMed Aster RH, George JN, McMillan R, Ganguly P: Workshop on autoimmune (idiopathic) thrombocytopenic purpura: pathogenesis and new approaches to therapy. Am J Hematol. 1998, 58: 231-234. 10.1002/(SICI)1096-8652(199807)58:3<231::AID-AJH12>3.0.CO;2-C.CrossRefPubMed
15.
go back to reference Mazzucconi MG, Piola P, Arista MC, Bizzoni L, Antenucci A, Conti L: Modifications of lymphocyte subsets in autoimmune thrombocytopenic purpura patients submitted to splenectomy. Haematologica. 2000, 85: 776-777.PubMed Mazzucconi MG, Piola P, Arista MC, Bizzoni L, Antenucci A, Conti L: Modifications of lymphocyte subsets in autoimmune thrombocytopenic purpura patients submitted to splenectomy. Haematologica. 2000, 85: 776-777.PubMed
16.
go back to reference Chang CS, Li CY, Cha SS: Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med. 1993, 117: 981-985.PubMed Chang CS, Li CY, Cha SS: Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med. 1993, 117: 981-985.PubMed
17.
go back to reference Kuhne T, Elinder G, Blanchette VS, Garvey B: Current management issues of childhood and adult immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998, 424: 75-81.PubMed Kuhne T, Elinder G, Blanchette VS, Garvey B: Current management issues of childhood and adult immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998, 424: 75-81.PubMed
18.
go back to reference Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001, 97: 2549-2554. 10.1182/blood.V97.9.2549.CrossRefPubMed Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001, 97: 2549-2554. 10.1182/blood.V97.9.2549.CrossRefPubMed
19.
go back to reference Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S, .: Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995, 98: 436-442. 10.1016/S0002-9343(99)80342-8.CrossRefPubMed Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S, .: Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995, 98: 436-442. 10.1016/S0002-9343(99)80342-8.CrossRefPubMed
20.
go back to reference Karpatkin S: Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997, 349: 1531-1536. 10.1016/S0140-6736(96)12118-8.CrossRefPubMed Karpatkin S: Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997, 349: 1531-1536. 10.1016/S0140-6736(96)12118-8.CrossRefPubMed
Metadata
Title
Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)
Authors
Fotios P Panitsas
Athanasia Mouzaki
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Hematology / Issue 1/2004
Electronic ISSN: 2052-1839
DOI
https://doi.org/10.1186/1471-2326-4-4

Other articles of this Issue 1/2004

BMC Hematology 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine